{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:04:13Z","timestamp":1792800253359,"version":"4.5.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is a rare autoimmune disease characterized by fatigable weakness of the voluntary muscles and can exacerbate to life-threatening myasthenic crisis (MC), requiring intensive care treatment. Routine laboratory parameters are a cost-effective and widely available method for estimating the clinical outcomes of several diseases, but so far, such parameters have not been established to detect disease progression in MG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of selected laboratory parameters related to inflammation and hemogram for MG patients with MC compared to MG patients without MC. To identify potential risk factors for MC, we applied time-varying Cox regression for time to MC and, as a sensitivity analysis, generalized estimating equations logistic regression for the occurrence of MC at the next patient visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>15 of the 58 examined MG patients suffered at least one MC. There was no notable difference in the occurrence of MC by antibody status or sex. Both regression models showed that higher counts of basophils (per 0.01 unit increase: HR\u2009=\u20091.32, 95% CI\u2009=\u20091.02\u20131.70), neutrophils (per 1 unit increase: HR\u2009=\u20091.40, 95% CI\u2009=\u20091.14\u20131.72), potentially leukocytes (per 1 unit increase: HR\u2009=\u20091.15, 95% CI\u2009=\u20090.99\u20131.34), and platelets (per 100\u2009units increase: HR\u2009=\u20091.54, 95% CI\u2009=\u20090.99\u20132.38) may indicate increased risk for a myasthenic crisis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This pilot study provides proof of the concept that increased counts of basophils, neutrophils, leukocytes, and platelets may be associated with a higher risk of developing MC in patients with MG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2024.1297997","type":"journal-article","created":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T23:29:00Z","timestamp":1708903740000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Identifying patients at risk for myasthenic crisis with hemogram and inflammation-related laboratory parameters \u2013 a pilot study"],"prefix":"10.3389","volume":"15","author":[{"given":"Anne","family":"Mehnert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivan","family":"Bershan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jil","family":"Kollmus-Heege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Gerischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meret Luise","family":"Herdick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lehnerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Scheibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Stascheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair M.","family":"Buchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mergenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis \u2013 autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2017","journal-title":"Ann N Y Acad Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jemermed.2017.06.009","article-title":"Myasthenia gravis and crisis: evaluation and management in the emergency department","volume":"53","author":"Roper","year":"2017","journal-title":"J Emerg Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1756286419864497","DOI":"10.1177\/1756286419864497","article-title":"Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis","volume":"12","author":"Gamez","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases","volume":"94","author":"Neumann","year":"2020","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1177\/0300060516669893","article-title":"Predictors of extubation outcomes following myasthenic crisis","volume":"44","author":"Liu","year":"2016","journal-title":"J Int Med Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in us hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1007\/s00415-022-11023-z","article-title":"Seronegative myasthenic crisis: a multicenter analysis","volume":"269","author":"Mergenthaler","year":"2022","journal-title":"J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1468-1331.1998.520137.x","article-title":"The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit","volume":"5","author":"O'Riordan","year":"1998","journal-title":"Eur J Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s10072-014-1659-y","article-title":"Predictors of outcome of myasthenic crisis","volume":"35","author":"Kalita","year":"2014","journal-title":"Neurol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1007\/s00415-021-10603-9","article-title":"Musk-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation","volume":"268","author":"K\u00f6nig","year":"2021","journal-title":"J Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/0885066620967646","article-title":"Early tracheostomy is associated with shorter ventilation time and duration of Icu stay in patients with myasthenic crisis-a multicenter analysis","volume":"37","author":"Angstwurm","year":"2022","journal-title":"J Intensive Care Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12883-019-1384-5","article-title":"Myasthenic crisis treated in a Chinese neurological intensive care unit: clinical features, mortality, outcomes, and predictors of survival","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke","year":"2022","journal-title":"J Neuroinflammation"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1080\/00207454.2020.1759592","article-title":"The correlation of neutrophil-to-lymphocyte ratio with the presence and short-time curative effect of myasthenia gravis in children: a retrospectively study","volume":"131","author":"Jiang","year":"2021","journal-title":"Int J Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"76099","DOI":"10.18632\/oncotarget.18546","article-title":"The correlation of neutrophil-to-lymphocyte ratio with the presence and activity of myasthenia gravis","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12883-021-02412-4","article-title":"Hemogram parameters can predict in-hospital mortality of patients with myasthenic crisis","volume":"21","author":"Hsu","year":"2021","journal-title":"BMC Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1101\/2023.09.19.23295421","article-title":"Identifying patients at risk for myasthenic crisis with hemogram and inflammation-related laboratory parameters \u2013 a pilot study","author":"Mehnert","year":"2023","journal-title":"medRxiv"},{"key":"ref24","volume-title":"R: A language and environment for statistical computing","year":"2021"},{"key":"ref25","author":"Therneau","year":"2021"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-4757-3294-8_3","article-title":"The Cox model","volume-title":"Modeling survival data: extending the Cox model","author":"Therneau","year":"2000"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v015.i02","article-title":"The R package Geepack for generalized estimating equations","volume":"15","author":"H\u00f8jsgaard","year":"2005","journal-title":"J Stat Softw"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1007\/s00415-020-10264-0","article-title":"Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review","volume":"268","author":"Lotan","year":"2021","journal-title":"J Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000512077","article-title":"Exacerbation rate in generalized myasthenia gravis and its predictors","volume":"84","author":"Abuzinadah","year":"2021","journal-title":"Eur Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jneuroim.2015.03.018","article-title":"Prognostic factors for exacerbations and emergency treatments in myasthenia gravis","volume":"282","author":"de Meel","year":"2015","journal-title":"J Neuroimmunol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1053\/j.semtcvs.2019.09.002","article-title":"Risk factors for the exacerbation of myasthenic symptoms after surgical therapy for myasthenia gravis and thymoma","volume":"32","author":"Kato","year":"2020","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"116530","DOI":"10.1016\/j.jns.2019.116530","article-title":"Preoperative risks of post-operative myasthenic crisis (Pomc): a meta-analysis","volume":"407","author":"Akaishi","year":"2019","journal-title":"J Neurol Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/ana.25087","article-title":"A clinical predictive score for postoperative myasthenic crisis","volume":"82","author":"Kanai","year":"2017","journal-title":"Ann Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000503961","article-title":"Predictive score for in-hospital mortality of myasthenic crisis: a retrospective Chinese cohort study","volume":"81","author":"Lv","year":"2019","journal-title":"Eur Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00415-018-8751-9","article-title":"Myasthenia gravis and infectious disease","volume":"265","author":"Gilhus","year":"2018","journal-title":"J Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.jacc.2008.01.034","article-title":"Thrombocytopenia and mortality in infective endocarditis","volume":"51","author":"Sy","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5414\/CN107471","article-title":"The impact of anemia on renal recovery and survival in acute kidney injury","volume":"79","author":"Hu","year":"2013","journal-title":"Clin Nephrol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/s0002-9149(03)00651-9","article-title":"Leukocytosis and adverse hospital outcomes after acute myocardial infarction","volume":"92","author":"Menon","year":"2003","journal-title":"Am J Cardiol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1475-2840-5-8","article-title":"Anemia is an independent risk for mortality after acute myocardial infarction in patients with and without diabetes","volume":"5","author":"Shu","year":"2006","journal-title":"Cardiovasc Diabetol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.alit.2017.04.007","article-title":"Emerging roles of basophils in allergic inflammation","volume":"66","author":"Miyake","year":"2017","journal-title":"Allergol Int"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","article-title":"Ige, mast cells, basophils, and eosinophils","volume":"125","author":"Stone","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1101\/2023.08.19.23294175","article-title":"Classifying the risk for myasthenic crisis using data-driven explainable machine learning with informative feature design and variance control \u2013 a pilot study","author":"Bershan","year":"2023","journal-title":"medRxiv"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1297997\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T23:29:04Z","timestamp":1708903744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1297997\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":44,"alternative-id":["10.3389\/fneur.2024.1297997"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1297997","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.09.19.23295421","asserted-by":"object"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"article-number":"1297997"}}